Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$20.15 -1.2%	$23.43	$12.21 ▼ $40.70	$563.30M	-0.2	748,055 shs	93,192 shs
CABA Cabaletta Bio	$1.50 -0.3%	$1.61	$0.99 ▼ $6.14	$135.82M	2.74	1.53 million shs	646,641 shs
PVLA Palvella Therapeutics	$53.07 -6.0%	$34.88	$11.17 ▼ $57.19	$586.95M	-0.01	97,981 shs	54,732 shs
XNCR Xencor	$8.01 -0.2%	$8.30	$6.92 ▼ $27.24	$569.51M	0.89	761,638 shs	258,648 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+2.20%	+1.24%	-23.28%	-9.57%	-44.63%
CABA Cabaletta Bio	-1.96%	-5.06%	-11.24%	-21.47%	-73.96%
PVLA Palvella Therapeutics	+5.00%	+11.92%	+41.59%	+127.80%	+5,644,999,900.00%
XNCR Xencor	+1.52%	+6.79%	-11.18%	+3.62%	-53.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	1.9237 of 5 stars	3.4	0.0	0.0	2.3	2.5	0.6
CABA Cabaletta Bio	2.526 of 5 stars	3.5	4.0	0.0	1.6	0.8	0.6
PVLA Palvella Therapeutics	2.7532 of 5 stars	3.5	0.0	0.0	2.7	2.5	0.6
XNCR Xencor	3.6884 of 5 stars	3.4	0.0	3.9	2.6	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$46.13	128.91% Upside
CABA Cabaletta Bio	3.00	Buy	$14.43	865.12% Upside
PVLA Palvella Therapeutics	3.09	Buy	$58.50	10.23% Upside
XNCR Xencor	2.75	Moderate Buy	$23.71	196.24% Upside

Current Analyst Ratings Breakdown

Latest CABA, XNCR, ANAB, and PVLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $15.00
8/19/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $66.00
8/15/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $75.00
8/15/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $60.00
8/12/2025	ANAB AnaptysBio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $20.00
8/7/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $45.00
8/7/2025	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $27.00
8/7/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $26.00
8/5/2025	PVLA Palvella Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$54.00
8/4/2025	PVLA Palvella Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$90.00
7/24/2025	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $80.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$123.16M	4.58	N/A	N/A	($1.60) per share	-12.59
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.95 per share	N/A
PVLA Palvella Therapeutics	$42.81M	13.71	N/A	N/A	$4.32 per share	12.28
XNCR Xencor	$146.93M	3.89	N/A	N/A	$8.70 per share	0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.48	N/A	N/A	N/A	-107.66%	-366.98%	-30.58%	11/4/2025 (Estimated)
CABA Cabaletta Bio	-$115.86M	-$2.71	N/A	N/A	N/A	N/A	-92.11%	-74.08%	11/13/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-62.30%	-43.34%	11/12/2025 (Estimated)
XNCR Xencor	-$232.62M	-$2.40	N/A	N/A	N/A	-121.52%	-25.75%	-18.19%	11/5/2025 (Estimated)

Latest CABA, XNCR, ANAB, and PVLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.78	-$0.86	-$0.08	-$0.86	N/A	N/A
8/7/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	-$0.73	-$0.02	-$0.73	$4.17 million	N/A
8/6/2025	Q2 2025	ANAB AnaptysBio	-$1.50	-$1.34	+$0.16	-$1.34	$11.55 million	$22.26 million
8/6/2025	Q2 2025	XNCR Xencor	-$0.78	-$0.41	+$0.37	-$0.41	$22.59 million	$43.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.22	8.22
CABA Cabaletta Bio	N/A	4.78	4.78
PVLA Palvella Therapeutics	N/A	7.67	7.67
XNCR Xencor	N/A	5.34	5.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
CABA Cabaletta Bio	N/A
PVLA Palvella Therapeutics	40.11%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
CABA Cabaletta Bio	11.25%
PVLA Palvella Therapeutics	20.50%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	28.00 million	18.62 million	Optionable
CABA Cabaletta Bio	50	91.46 million	81.18 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
XNCR Xencor	280	71.32 million	67.93 million	Optionable

CABA, XNCR, ANAB, and PVLA Headlines

Recent News About These Companies

Xencor to Participate at Upcoming Investor Conferences

August 27 at 4:01 PM | businesswire.com

Vanguard Group Inc. Trims Stake in Xencor, Inc. $XNCR

August 26 at 3:04 AM | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from Brokerages

August 25 at 3:07 AM | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by Analysts

August 24, 2025 | marketbeat.com

Aberdeen Group plc Grows Holdings in Xencor, Inc. $XNCR

August 23, 2025 | marketbeat.com

Royal Bank Of Canada Lowers Xencor (NASDAQ:XNCR) Price Target to $15.00

August 23, 2025 | americanbankingnews.com

Xencor, Inc. $XNCR Stock Holdings Lifted by Public Sector Pension Investment Board

August 22, 2025 | marketbeat.com

Xencor price target lowered to $15 from $32 at RBC Capital

August 21, 2025 | msn.com

Q3 Earnings Estimate for Xencor Issued By Leerink Partnrs

August 11, 2025 | marketbeat.com

Wedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)

August 11, 2025 | marketbeat.com

William Blair Analysts Boost Earnings Estimates for Xencor

August 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.37 EPS

August 10, 2025 | marketbeat.com

Xencor (XNCR) Receives a Buy from Leerink Partners

August 9, 2025 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

August 9, 2025 | finance.yahoo.com

Xencor (XNCR) Q2 Revenue Jumps 82%

August 9, 2025 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst Downgrade

August 8, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Wedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00

August 8, 2025 | marketbeat.com

Xencor price target lowered to $26 from $31 at Wedbush

August 8, 2025 | finance.yahoo.com

Primecap Management Co. CA Has $103.86 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

August 8, 2025 | marketbeat.com

XTX Topco Ltd Acquires 35,627 Shares of Xencor, Inc. (NASDAQ:XNCR)

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, XNCR, ANAB, and PVLA Company Descriptions

AnaptysBio NASDAQ:ANAB

$20.15 -0.25 (-1.23%)

As of 03:52 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Cabaletta Bio NASDAQ:CABA

$1.50 -0.01 (-0.33%)

As of 03:52 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Palvella Therapeutics NASDAQ:PVLA

$53.07 -3.38 (-5.99%)

As of 03:33 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Xencor NASDAQ:XNCR

$8.01 -0.02 (-0.19%)

As of 03:52 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time